Compass Therapeutics (CMPX) vs Cardiol Therapeutics (CRDL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 24.5% versus a loss of 71.7%. Over five years, CRDL leads with a -66.4% price change compared with -68.2% for CMPX. Compass Therapeutics is the larger company by market cap ($177.2 million vs $160.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | CRDL |
|---|---|---|
| Share price | $0.984 | $1.32 |
| Market cap | $177.21M | $160.40M |
| 1-day change | -3.53% | 0.00% |
| YTD return | -81.01% | +38.36% |
| 1-year return | -71.75% | +24.53% |
| 5-year return | -68.22% | -66.41% |
| EPS (TTM) | $-0.39 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.88 | $2.34 |
| 52-week low | $0.829 | $0.88 |
| Distance from 52-week high | -85.70% | -43.59% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +453.86% | +533.33% |
| Average volume | 4.06M | 1.44M |
| Shares outstanding | 180.09M | 121.51M |
| Employees | 39 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed CMPX by 96.3 percentage points over the past year.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
CMPX vs CRDL FAQ
Which is bigger, Compass Therapeutics or Cardiol Therapeutics?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $177.21M compared with $160.40M for Cardiol Therapeutics (CRDL).
Which stock has performed better over the past year, CMPX or CRDL?
CRDL returned +24.53% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Cardiol Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.